Bispecific Antibody Outperforms PD-1 Inhibitor in Advanced Lung Cancer
CHICAGO -- A new bispecific antibody, ivonescimab, combined with chemotherapy showed superior results in treating advanced non-small cell lung cancer (NSCLC) at the ASCO conference. The HARMONi-6…